- Home
- CUBA vs BRNS Comparison
CUBA vs BRNS Comparison
Compare CUBA & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBA
- BRNS
- Stock Information
- Founded
- CUBA 1992
- BRNS 2016
- Country
- CUBA United States
- BRNS United Kingdom
- Employees
- CUBA N/A
- BRNS N/A
- Industry
- CUBA Investment Managers
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- CUBA Finance
- BRNS Health Care
- Exchange
- CUBA Nasdaq
- BRNS Nasdaq
- Market Cap
- CUBA 39.0M
- BRNS 36.0M
- IPO Year
- CUBA N/A
- BRNS 2021
- Fundamental
- Price
- CUBA $2.52
- BRNS $1.00
- Analyst Decision
- CUBA
- BRNS Strong Buy
- Analyst Count
- CUBA 0
- BRNS 1
- Target Price
- CUBA N/A
- BRNS $3.00
- AVG Volume (30 Days)
- CUBA 93.9K
- BRNS 17.8K
- Earning Date
- CUBA 01-01-0001
- BRNS 08-07-2025
- Dividend Yield
- CUBA 20.83%
- BRNS N/A
- EPS Growth
- CUBA N/A
- BRNS N/A
- EPS
- CUBA N/A
- BRNS N/A
- Revenue
- CUBA N/A
- BRNS $14,969,000.00
- Revenue This Year
- CUBA N/A
- BRNS N/A
- Revenue Next Year
- CUBA N/A
- BRNS N/A
- P/E Ratio
- CUBA N/A
- BRNS N/A
- Revenue Growth
- CUBA N/A
- BRNS 4381.74
- 52 Week Low
- CUBA $2.25
- BRNS $0.64
- 52 Week High
- CUBA $4.14
- BRNS $1.58
- Technical
- Relative Strength Index (RSI)
- CUBA 52.95
- BRNS 55.94
- Support Level
- CUBA $2.46
- BRNS $0.90
- Resistance Level
- CUBA $2.55
- BRNS $1.10
- Average True Range (ATR)
- CUBA 0.04
- BRNS 0.06
- MACD
- CUBA 0.00
- BRNS 0.01
- Stochastic Oscillator
- CUBA 63.64
- BRNS 60.00
About CUBA Herzfeld Caribbean Basin Fund Inc. (The)
Herzfeld Caribbean Basin Fund Inc operates as a closed-end management investment company. The company's investment objective is to obtain long-term capital appreciation. The firm offers customized discretionary account management and fund management services to individual and institutional investors. The fund invests in equity and equity-linked securities of public and private companies, including United States-based companies, whose securities are traded principally on a stock exchange in a Caribbean Basin Country. The fund's revenue source is through the dividends it receives. Its investments are geographically allocated in the United States followed by Mexico, Puerto Rico, and other countries.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.